

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets




(11) Publication number:

0 533 267 A1

(12)


EUROPEAN PATENT APPLICATION(21) Application number: **92202805.5**(51) Int. Cl.⁵: **C07D 213/56, A61K 31/50**(22) Date of filing: **14.09.92**(30) Priority: **18.09.91 GB 9119932**(43) Date of publication of application:
24.03.93 Bulletin 93/12(64) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**(71) Applicant: **GLAXO GROUP LIMITED**
Glaxo House, Berkeley Avenue
Greenford, Middlesex UB6 0NN(GB)(72) Inventor: **Oxford, Alexander William**
Glaxo Group Research Limited, Park Road
Ware, Hertfordshire SG12 0DG(GB)Inventor: **Mitchell, William Leonard**
Glaxo Group Research Limited, Park Road
Ware, Hertfordshire SG12 0DG(GB)Inventor: **Bradshaw, John**
Glaxo Group Research Limited, Park Road
Ware, Hertfordshire SG12 0DG(GB)Inventor: **Clitherow, John Watson**
Glaxo Group Research Limited, Park Road
Ware, Hertfordshire SG12 0DG(GB)(74) Representative: **James, Stephen Richard et al**
Glaxo Holdings plc Glaxo House Berkeley
Avenue
Greenford, Middlesex UB6 0NN (GB)(94) **Benzanilide derivatives as 5-HT_{1D} antagonists.**

(97) The invention provides compounds of the general formula (I) :-



or a physiologically acceptable salt or solvate thereof
wherein

R¹ represents a hydrogen atom, a halogen atom or a group selected from C₁₋₆ alkyl and C₁₋₆ alkoxy;
R² represents a pyridinyl group optionally substituted by one or two substituents selected from halogen atoms, C₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkoxyC₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, -CN, -NO₂, -CO₂R⁶, -COR⁶, -CONR⁶R⁷ and -(CH₂)_mOC(O)C₁₋₄ alkyl;
R³ represents the group



R⁴ and R⁵, which may be the same or different, each independently represent a hydrogen atom or a halogen


EP 0 533 267 A1

atom or a group selected from hydroxy, C₁-₆alkoxy and C₁-₆alkyl;
R⁶, R⁷ and R⁸, which may be the same or different, each independently represent a hydrogen atom or a
C₁-₆alkyl group; and
m represents zero or an integer from 1 to 3.

The compounds may be used in the treatment or prophylaxis of depression and other CNS disorders.

This invention relates to novel benzanilide derivatives, to processes for their preparation, and to pharmaceutical compositions containing them.

According to the invention we provide compounds of the general formula (I) :-




or a physiologically acceptable salt or solvate (eg hydrate) thereof, in which

R¹ represents a hydrogen atom, a halogen atom or a group selected from C₁₋₆ alkyl and C₁₋₆ alkoxy;

R² represents a pyridinyl group optionally substituted by one or two substituents selected from halogen atoms, C₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkoxyC₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, -CN, -NO₂, -CO₂R⁶, -COR⁶, -CONR⁶R⁷ and -(CH₂)_mOC(O)C₁₋₄ alkyl;

R³ represents the group



R⁴ and R⁵, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C₁₋₆ alkoxy and C₁₋₆ alkyl;

R⁶, R⁷ and R⁸, which may be the same or different, each independently represent a hydrogen atom or a C₁₋₆ alkyl group; and

m represents zero or an integer from 1 to 3.

It is to be understood that the present invention encompasses all geometric and optical isomers of the compounds of general formula (I) and their mixtures including the racemic mixtures thereof.

Physiologically acceptable salts of the compounds of general formula (I) include acid addition salts formed with inorganic or organic acids (for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p-toluenesulphonates, methanesulphonates, sulphamates, ascorbates, tartrates, citrates, oxalates, maleates, salicylates, fumarates, succinates, lactates, glutarates, glutaconates, acetates or tricarballoylates) and, where appropriate, inorganic base salts such as alkali metal salts (for example sodium salts).

In the compounds of general formula (I), the term 'C₁₋₆ alkyl' or 'C₁₋₆ alkoxy' as a group or part of a group means that the group is straight or branched and consists of 1 to 6 carbon atoms. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy. The term 'halogen' within the definition of R² means fluorine, chlorine, bromine or iodine.

A preferred group of compounds of general formula (I) is that wherein R² is a 3-pyridinyl, or more preferably a 4-pyridinyl, group optionally substituted by one or two substituents as defined in general formula (I).

Another preferred group of compounds of general formula (I) is that wherein R² is a pyridinyl group optionally substituted by a single substituent, in particular a C₁₋₆ alkyl, especially methyl, group. Particularly preferred are those compounds wherein the substituent on the pyridinyl group is in a position ortho to the bond to the phenyl ring A in general formula (I).

A further preferred group of compounds of general formula (I) is that wherein R¹ is a hydrogen atom, a halogen atom, especially a fluorine atom, or a group selected from C₁₋₃ alkyl, especially methyl, and C₁₋₃ alkoxy, especially methoxy.

Another preferred group of compounds of general formula (I) is that wherein R⁴ is attached in the para-position relative to the amide linkage.

A further preferred group of compounds of general formula (I) is that wherein R⁴ is a hydrogen atom or a halogen atom, especially chlorine or fluorine, or a group selected from hydroxy, C₁₋₃ alkoxy, especially methoxy, and C₁₋₃ alkyl, especially methyl.

Also preferred is the group of compounds of general formula (I) wherein R⁵ is a hydrogen atom or a C₁₋₆ alkoxy, especially methoxy, group, particularly, R⁵ is a hydrogen atom.

A yet further preferred group of compounds of general formula (I) is that wherein R⁸ is a hydrogen atom or a C₁₋₆ alkyl, especially methyl, group.

Compounds of general formula (I) wherein R⁴ represents a hydroxy or methoxy group, R⁵ represents a hydrogen atom and R⁸ represents a methyl group are particularly preferred.

Particularly preferred compounds of general formula (I) include:-

N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl) benzamide;
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-methyl-3-pyridinyl)benzamide;
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;
and their physiologically acceptable salts and solvates.

Further preferred compounds of general formula (I) include:

N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2-methyl-4-(4-pyridinyl)benzamide;
N-[4-methyl-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
N-[4-chloro-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
N-[4-fluoro-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
N-[4-methoxy-3-(4-methyl-1-piperazinyl)-4-(3-methyl-4-pyridinyl)benzamide;
N-[6-fluoro-4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;
N-[4-bromo-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;
N-[3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
4-(4-pyridinyl)-2-methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide;
N-[4-hydroxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl) benzamide;
and their physiologically acceptable salts and solvates.

5-Hydroxytryptamine (serotonin) is a neurotransmitter which is widely distributed within the central nervous system (CNS), platelets and the gastrointestinal tract. Changes in transmission in serotonergic pathways in the CNS are known to modify, for example, mood, psychomotor activity, appetite, memory and blood pressure. Release of 5-hydroxytryptamine from platelets can mediate vasospasm while changes in free 5-hydroxytryptamine levels in the gastrointestinal tract can modify secretion and motility.

Abundant pharmacological studies have led to the discovery of multiple types of receptors for 5-hydroxytryptamine, thus providing a molecular basis to the diversity of its actions. These receptors are classed as 5-HT₁, 5-HT₂ and 5-HT₃, with 5-HT₁ receptors being sub-classified as 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1C}, 5-HT_{1D} and 5-HT_{1D}(like) receptors. The identification of these classes and sub-classes of receptor is based mainly on radiological binding studies.

Compounds having a selective antagonist action at 5-HT_{1D} receptors such as those described herein may exhibit a beneficial effect on subjects suffering from CNS disorders.

Accordingly, in a further aspect of the present invention, there is provided a method of treating a patient suffering from a CNS disorder, which method comprises administering to the patient an effective amount of a 5-HT_{1D} antagonist. The patient is preferably a human patient.

In another aspect of the present invention, there is provided a 5-HT_{1D} antagonist for use in the manufacture of a medicament for the treatment of a CNS disorder.

In the present specification, a 5-HT_{1D} antagonist is a non-naturally occurring (synthetic) compound that specifically and selectively antagonises 5-HT_{1D} receptors, i.e. - blocks the specific actions of 5-hydroxytryptamine mediated by the 5-HT_{1D} receptor. Such compounds may be identified by a high level of affinity (pK_i ≥ 8) in the in vitro human cortex and guinea-pig striatum radioligand binding assays described by Hoyer et al, *Neuroscience Letters*, 1988, 85, p357-362. Activity at 5-HT_{1D} receptors may be confirmed in vivo using the guinea pig rotation model described by G A Higgins et al, *Br. J. Pharmacol.*, 1991, 102, p305-310.

A 5-HT_{1D} antagonist for use in the present method of treatment must be selective for 5-HT_{1D} receptors. In the present specification, this means that the 5-HT_{1D} antagonist must be 30 or more times more selective for 5-HT_{1D} receptors than 5-HT_{1A}, 5-HT_{1C} or 5-HT₂ receptors.

According to this definition the affinity of a compound for 5-HT_{1A}, 5-HT_{1C} and/or 5-HT₂ receptors is measured using the in vitro tests described in the following publications:

5-HT_{1A} Gozlan et al, *Nature*, 1983, 305, p140-142
5-HT_{1C} Pazos et al, *Eur. J. Pharmacol.*, 1984, 106, p531-538
5-HT₂ Humphrey et al, *Br. J. Pharmacol.*, 1988, 94, p1123-1132 (rabbit aorta model).

Thus, for example, compounds of the present invention have been shown to inhibit 5-hydroxytryptamine induced contraction of the dog isolated saphenous vein and to antagonise the 5-hydroxytryptamine induced inhibition of neurotransmission in central and peripheral neurones.

5-HT_{1D} Antagonists, and in particular the compounds of the present invention, may therefore be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal affective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; and disorders of eating behaviour, including anorexia nervosa and bulimia nervosa. Other CNS disorders include Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.

5-HT_{1D} Antagonists, and in particular compounds of the present invention, may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction.

Therefore, according to a second aspect of the invention, we provide a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy.

According to a further aspect of the present invention, we therefore provide a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.

According to another aspect of the invention, we provide the use of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a therapeutic agent for the treatment of the aforementioned disorders.

According to a further aspect of the invention, we provide, a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof.

In particular, according to another aspect of the invention, we provide a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.

It will be appreciated that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as tricyclic antidepressants (e.g. amitriptyline, dothiepin, doxepin, trimipramine, butriptyline, clomipramine, desipramine, imipramine, iprindole, lofepramine, nortriptyline or protriptyline), monoamine oxidase inhibitors (e.g. isocarboxazid, phenelzine or tranylcyclopramine) or 5-HT reuptake inhibitors (e.g. fluvoxamine, sertraline, fluoxetine or paroxetine), and/or antiparkinsonian agents such as dopaminergic antiparkinsonian agents (e.g. levodopa, preferably in combination with a peripheral decarboxylase inhibitor e.g. benserazide or carbidopa, or a dopamine agonist e.g. bromocriptine, lysuride or pergolide). It is to be understood that the present invention covers the use of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof in combination with one or more other therapeutic agents.

Thus there is provided in a further or alternative aspect of the present invention a compound of general formula (I) or a physiologically acceptable salt or solvate thereof and an antidepressant agent in the presence of each other in the human or non-human animal body for use in the treatment of the aforementioned disorders.

In a particular aspect of the present invention there is provided a compound of general formula (I) or a physiologically acceptable salt or solvate thereof and an antiparkinsonian agent such as a dopaminergic antiparkinsonian agent, e.g. levodopa, and a peripheral decarboxylase inhibitor, e.g. benserazide or carbidopa, or a dopamine agonist e.g. bromocriptine, lysuride or pergolide, in the presence of each other in the human or non-human animal body for use in the treatment of Parkinson's disease, dementia in parkinsonism, neuroleptic induced parkinsonism and tardive dyskinesias.

In using a compound of general formula (I) or a physiologically acceptable salt or solvate thereof and one or more therapeutic agents it may be preferable to employ the active ingredients in the form of separate pharmaceutical formulations. A combined formulation can be used, however, in such a combined formulation the active ingredients must of course be stable and mutually compatible in the particular formulation employed.

It will be appreciated that administration of the active ingredients to a human or non-human patient may be simultaneous, separate or sequential. Where administration is not simultaneous, the delay in administering the second of the active ingredients should not be such as to lose the beneficial effect of the combination.

While it is possible that a compound of general formula (I) may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.

The compounds of general formula (I) and their physiologically acceptable salts and solvates may be formulated for administration in any convenient way, and the invention therefore also includes within its

scope pharmaceutical compositions comprising at least one compound of general formula (I) or a physiologically acceptable salt or solvate thereof. Such compositions may be presented for use in a conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Thus, the compositions according to the invention may be formulated for oral, buccal, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred.

Tablets and capsules for oral administration may contain conventional excipients such as binding agents; for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycolate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methylcellulose, glucose/sugar syrup, gelatin, hydroxypropyl methylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The compositions may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The composition according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

For administration by inhalation either orally or nasally the compositions according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation the compositions according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.

The pharmaceutical formulations according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.

The compositions according to the invention may be prepared by mixing the various ingredients using conventional means.

It will be appreciated that the amount of a compound of general formula (I) required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or veterinarian. In general, however, a proposed dose of the compounds of the invention for administration in man is 0.5 to 1000mg, preferably 1 to 200mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.

The compounds of the invention may be prepared by a number of processes as described in the following. In describing the processes which may be used for preparing the compounds of general formula (I) or intermediates useful in the preparation thereof, any of R¹-R⁸ and m in the various formulae are as defined in formula (I) unless otherwise stated.


It will be appreciated that in the following methods for the preparation of compounds of general formula (I), for certain reaction steps it may be necessary to protect various reactive substituents in the starting materials for a particular reaction and subsequently to remove the protecting group. Such protection and

subsequent deprotection may be particularly pertinent where R^6 , R^7 and/or R^8 in intermediates used to prepare compounds of general formula (I) are hydrogen atoms. Standard protection and deprotection procedures can be employed, for example formation of a phthalimide (in the case of a primary amine), benzyl, trityl, benzyloxycarbonyl or trichloroethoxycarbonyl derivatives. Subsequent removal of the protecting group is achieved by conventional procedures. Thus a phthalimide group may be removed by treatment with hydrazine or a primary amine, for example methylamine. Benzyl or benzyloxycarbonyl groups may be removed by hydrogenolysis in the presence of a catalyst e.g. palladium, and trichloroethoxycarbonyl derivatives may be removed by treatment with zinc dust. Trityl groups may be removed under acidic conditions using standard procedures.


It may also be necessary in some cases to protect carboxylic acid groups (e.g. as esters) or aldehyde or ketone groups (e.g. as acyclic or cyclic acetals or ketals or as thioacetals or thioketals). Subsequent removal of these protecting groups is achieved by conventional procedures. Thus for example alkyl esters may be removed under conditions of acidic or basic hydrolysis, benzyl esters may be removed by hydrogenolysis in the presence of a catalyst e.g. palladium. Acyclic or cyclic acetals or ketals may be removed under conditions of acidic hydrolysis and thioacetals and thioketals may be removed using a mercuric salt.

Hydroxyl groups may also need protection and these may be adequately protected under amenable conditions as their esters or trialkylsilyl, tetrahydropyran and benzyl ethers. Such derivatives may be deprotected by standard procedures.

According to one general process (1), the compounds of general formula (I) may be prepared by a carbonylation reaction involving an aniline (II)



(where R^3 , R^4 and R^5 are as defined in general formula (I)) and a halophenyl compound (III)




(where Y represents a halogen atom e.g. bromine or iodine or the group $-\text{OSO}_2\text{CF}_3$, and R^1 and R^2 are as defined in general formula (I)).

The reaction takes place, for example, in the presence of carbon monoxide using a palladium salt as a catalyst. The reaction is effected in the presence of a suitable base e.g. a trialkylamine such as triethylamine or tri-n-butylamine and may be conducted in a suitable solvent such as an amide e.g. dimethylformamide or a nitrile eg acetonitrile at a temperature within the range of -10°C to $+150^\circ\text{C}$.

Suitable palladium salts for the reaction include triarylphosphine palladium (II) salts such as bis-(triphenylphosphine)palladium (II) chloride.

According to another general process (2), the compounds of general formula (I) may be prepared by treating a compound of formula (IV)




10 with an amine dihalide of formula (V)



(where Hal is a chlorine, bromine or iodine atom).


15 The reaction may conveniently take place in the presence of a polar solvent such as an alcohol (e.g. n-butanol) or a nitrile (e.g. acetonitrile), optionally in the presence of a base, for example, an alkali metal carbonate such as sodium carbonate or potassium carbonate, or alternatively in a non-polar solvent (e.g. chlorobenzene) in the absence of a base. The reactions may conveniently be carried out at an elevated temperature, for example, reflux.

20 According to another general process (3), the compounds of general formula (I) may be prepared by reacting an aniline of formula (II) with an activated carboxylic acid derivative of formula (VI)



30 (where Z is a leaving group).

Suitable activated carboxylic acid derivatives represented in formula (VI) include acyl halides (e.g. acid chlorides) and acid anhydrides including mixed anhydrides (e.g. acid formic anhydride). These activated derivatives may be formed from the corresponding acid of formula (VII)




45 by well known procedures. For example, acid chlorides may be prepared by reaction with phosphorus pentachloride, thionyl chloride or oxalyl chloride and acid anhydrides may be prepared by reaction with an appropriate acid anhydride (e.g. trifluoroacetic anhydride), an acid chloride (e.g. acetyl chloride), an alkyl or aralkyl haloformate (e.g. ethyl or benzyl chloroformate) or methanesulphonyl chloride.

50 Activated carboxylic acid derivatives of formula (VI) may also be prepared *in situ* by the reaction of the corresponding acids of formula (VII), with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphoryl azide.


The conditions under which the activated carboxylic acid derivatives of formula (VI) are formed and subsequently reacted with the anilines of formula (II) will depend upon the nature of the activated derivative. However, in general the reaction between the compounds (II) and (VI) may be carried out in a non-aqueous medium such as, for example, dimethylformamide, tetrahydrofuran, acetonitrile or a halohydrocarbon such as dichloromethane at a temperature within the range -25°C to +150°C. The reaction may optionally be carried out in the presence of a base such as triethylamine or pyridine and the base may also be used as the solvent for reaction.

Where acid chlorides are used, the reaction may be carried out using the Schotten-Baumann technique in the presence of a suitable base, for example, aqueous sodium hydroxide, conveniently at a temperature between 0°C and 100°C, for example, room temperature.

According to another general process (4a), the compounds of general formula (I) may be prepared by treating a compound of formula (VIIIa)




(where Y represents a bromine or iodine atom or the group $-\text{OSO}_2\text{CF}_3$) with a compound of formula (IXa)



or an ester or an anhydride thereof.

Alternatively, according to the general process (4b), the compounds of general formula (I) may be prepared by treating a compound of formula (VIIIb)



or an ester or an anhydride thereof, with a compound of formula (IXb)



where Y represents a bromine or iodine atom or the group $-\text{OSO}_2\text{CF}_3$.

Both reactions may be effected in the presence of a transition metal catalyst such as $(\text{Ph}_3\text{P})_4\text{Pd}$ (where Ph represents phenyl) in a suitable solvent such as an ether (eg 1,2-dimethoxyethane or tetrahydrofuran) in the presence or absence of water, or an aromatic hydrocarbon (eg benzene). The reaction is preferably carried out in the presence of a base such as an alkali or alkaline earth metal carbonate (eg sodium carbonate) at a suitable temperature up to reflux.

Compounds of general formula (I) in which R^2 , R^4 and R^5 have a particular meaning may be converted into another compound of the invention by standard methods of interconversion.


For instance, when R^2 contains a hydroxy or alkoxy group and/or when R^4 and/or R^5 represents hydroxy or alkoxy these groups may be interchanged by standard methods of O-alkylation or O-dealkylation. Thus, for example, a compound in which R^4 represents hydroxy may be prepared by treating a corresponding compound in which R^4 represents methoxy with a reagent system capable of removing the methyl group e.g. a mercaptide such as sodium ethylmercaptide in a solvent such as dimethylformamide, lithium iodide in collidine, boron tribromide in a halohydrocarbon solvent e.g. methylene chloride or molten pyridine hydrochloride.

When R^2 contains a hydroxymethyl group this may be converted by oxidation into a corresponding compound of general formula (I) in which R^2 contains a group COR^6 (where R^6 is a hydrogen atom) or CO_2H . Thus, for example, oxidation may be effected using a suitable oxidising agent such as a manganese oxidising agent (eg manganese dioxide) in a solvent such as an ether (eg 1,4-dioxan) at a suitable temperature up to reflux, a chromium oxidising agent (eg Jones reagent) or pyridinium dichromate in a suitable solvent such as a halohydrocarbon (e.g. methylene chloride).


When R^2 contains an aldehyde group this may be converted by oxidation into a corresponding compound of general formula (I) in which R^2 contains a group CO_2H . Thus, for example, oxidation may be

effected using a suitable oxidising agent such as a source of silver (I) ions (e.g. silver nitrate) in aqueous alkali optionally in the presence of a cosolvent such as an alcohol (e.g. methanol).

Intermediates of formula (II) may be prepared from the corresponding compound of formula (X)




by reaction with a compound of formula (XI)




20 in the presence of acetic anhydride, followed by reduction of the diketopiperazine intermediate thus formed using for example, borane. The reaction may be carried out at a temperature between 50°C and reflux, and optionally in a solvent such as an ether, e.g. tetrahydrofuran, or toluene. The nitro group may be subsequently converted into an amine using standard methodology.

25 Alternatively, intermediates of formula (II) in which R4 is adjacent to R5, and R5 is a hydrogen atom, may be prepared by nitration of a compound of formula (XII)



40 using an appropriate nitrating system such as sulphuric acid and potassium nitrate, or nitronium tetrafluoroborate, in the presence of a solvent, for example, acetonitrile, or alternatively, where R8 is not a hydrogen atom, by nitrosation using, for example, sodium nitrite and a suitable acid such as sulphuric acid in solvent, for example, water, followed in each case by reduction of the nitro or nitroso group using standard methodology.

45 Intermediates of formula (IV) may be prepared by reduction of the corresponding nitro compound of general formula (XIII)




55 The reduction may be effected by catalytic hydrogenation using a metal catalyst such as palladium or platinum or oxides thereof, preferably, in a solvent such as an alcohol e.g. ethanol, or alternatively by using Raney nickel and hydrazine in a solvent such as an alcohol e.g. ethanol.

Intermediates of formula (XIII) may be prepared by condensing a compound of formula (VI) with a compound of formula (X) under the conditions of general process (3).

It will be appreciated that, where necessary, a halogen substituent may be converted into a carboxyl group using standard methodology thus, for example, intermediates of formula (VII) may be prepared from an intermediate of formula (III) by lithiation with, for example, n-butyl lithium followed by quenching with carbon dioxide.

Intermediates of formula (VIIIa) and (VIIIb) may be prepared by reaction of a compound of formula (II) with a compound of formula (XIVa) or (XIVb), respectively.



according to the method of general process (3).

The boronic acid intermediates of formulae (VIIIb), (IXa) and (XIVb) or their esters or anhydrides may be used in situ under the conditions described above for general process (4).

Intermediates of formula (VII) may be prepared by the reaction of a compound of formula (IXa) or (IXb) with a compound of formula (XIVa) or (XIVb), respectively, according to the method of general process (4).

Intermediates of formula (II) may also be prepared from the corresponding carboxylic acid using conventional procedures (e.g. by Curtius rearrangement).

Intermediates of formulae (V), (X), (XI), (XII), (XIVa) and (XIVb) are either known compounds or may be prepared by standard methodology or methods analogous to those described herein.

Physiologically acceptable acid addition salts of the compounds of formula (I) may be prepared by treating the corresponding free base with a suitable acid using conventional methods. Thus, for example, a generally convenient method of forming the acid addition salts is to mix appropriate quantities of the free base and the acid in an appropriate solvent eg an alcohol such as ethanol or an ester such as ethyl acetate.

Inorganic basic salts of compounds of formula (I) may be prepared by treating the corresponding acid of formula (I) (i.e. a compound of formula (I) in which R^2 contains a group CO_2H) with a suitable base using conventional methods.

Salts of compounds of formula (I) may also be converted to different physiologically acceptable salts of compounds of formula (I) using conventional methods.

The invention is illustrated but not limited by the following examples in which temperatures are in $^{\circ}\text{C}$. Thin layer chromatography (t.l.c.) was carried out on silica plates.

The following abbreviations are used:-

DMF - dimethylformamide; TEA - triethylamine; HMPA - hexamethylphosphoramide; DME-1,2-dimethoxyethane; THF - tetrahydrofuran; MSC - methanesulphonyl chloride; BTPC - bis(triphenylphosphine)palladium (II) chloride; DMA - dimethylamine; SPC - Short path chromatography carried out on silica (Merck 7747) unless otherwise stated. FCC - Flash column chromatography carried out on silica (Merck 9385). 'Dried' refers to drying using sodium sulphate or magnesium sulphate unless otherwise stated.

The following solvent systems are used:-

System A - dichloromethane:ethanol:0.88 ammonia; System B - dichloromethane:methanol:0.88 ammonia.

Intermediate 1

Methyl 4-methoxy-3-(4-methyl-1-piperazinyl)benzoate hydrochloride

A suspension of 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (1.92g) and methyl 3-amino-4-methoxybenzoate (1.81g) in n-butanol was refluxed with stirring for 19h. Anhydrous sodium carbonate (0.54g) was added and refluxing continued for 8.5h. The solvent was then removed to give an oil which was taken up in water (50ml) and 2N hydrochloric acid (50ml) and extracted with ethyl acetate (2x50ml). The acid solution was then basified with sodium bicarbonate and re-extracted with ethyl acetate (3x50ml). The extracts were dried and concentrated to a semi-solid (2.47g) which was absorbed from System A (200:8:1)

(5ml) onto Kieselge G (100g). Elution with the same solvent gave starting material and minor basic impurities. Further elution with System A (100:8:1) (450ml) gave first minor impurities and later fractions afforded the free base of the desired product as a gum (0.48g). This was taken up in methanol (5ml), filtered and treated with ethereal hydrogen chloride and diluted to 25ml with ethyl acetate. A cream coloured solid separated and was collected giving the title compound (0.586g), m.p. 190-194°. Recrystallisation from methanol:ethyl acetate afforded a sample for analysis.

Analysis Found:	C,55.7;	H,7.2;	N,9.2;	Cl,12.0
C ₁₄ H ₂₀ N ₂ O ₃ .HCl requires	C,55.9;	H,7.0;	N,9.3;	Cl,11.8%

Intermediate 2

15 4-Bromo-N-[(2-methoxy-5-nitro)phenyl]benzamide

To a stirred solution of 2-methoxy-5-nitrobenzenamine (1g) and 4-bromobenzoyl chloride (1.31g) in THF (5ml), was added sodium hydroxide (476mg) in water (5ml). The mixture was stirred at room temperature for 1.5h. Further THF (5ml) was added and stirring continued for 1h. The yellow precipitate was collected by
 20 filtration and triturated from ether (30ml) to give the title compound as yellow solid (1.34g).
 T.l.c. System A (350:8:1), Rf 0.65.

Intermediate 3

25 N-[(5-Amino-2-methoxy)phenyl]-4-bromobenzamide

Intermediate 2 (12.6g) was dissolved in THF (400ml) and hydrogenated at room temperature over 5% Rhodium on carbon (2.5g) for 14h. The catalyst was removed by filtration and washed with THF (500ml). The solvent was evaporated in vacuo to give the title compound as a brown crystalline solid (9.19g).
 30 T.l.c System A (350:8:1), Rf 0.21

Intermediate 4

4-Bromo-N-[(2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]benzamide

A suspension of Intermediate 3 (2g) and 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (1.539g) in butan-1-ol (30ml) was heated at reflux, under nitrogen for 18h. Anhydrous sodium carbonate (3.66g) was added and refluxing continued for a further 24h. The butanol was evaporated in vacuo to give a brown oil (7.6g). To this water (75ml) was added and the solution extracted with ethyl acetate (3 x 75ml).
 40 The dried extracts were evaporated in vacuo to give a brown oil. This was chromatographed on silica (Merck 7729, 160g) eluting with System A (250:8:1) to give the title compound as a pink solid (825mg), m.p. 116.5-117.5°C.

Intermediate 5

45 4-Methoxy-3-(4-methyl-1-piperazinyl)benzoic acid hydrazide

The free base of Intermediate 1 (2g) in methanol (20ml) was treated with hydrazine hydrate (4ml) and refluxed under nitrogen for 16h. The solution was evaporated and the residue then adsorbed from ethanol onto silica gel [Merck Art. 7734, 5g]. Purification by SPC eluting with System A (91:9:0.9) gave the title
 50 compound as an off-white solid (0.764g).
 T.l.c. System A (90:10:0.1), Rf 0.2.

Intermediate 64-Methoxy-3-(4-methyl-1-piperazinyl)benzenamine

5 A solution of Intermediate 5 (0.73g) in water (30ml) was mixed with concentrated hydrochloric acid (0.6ml), the solution cooled to 0 to 5°C and a solution of sodium nitrite (0.219g) in water (10ml) added during 5min. The solution was stirred at 0-5°C for 20min, then 1h at 23°C, and treated with concentrated hydrochloric acid (40ml) and acetic acid (40ml). The mixture was heated at reflux for 2h, cooled and poured into aqueous sodium hydroxide (5N; 260ml). The mixture was extracted with ethyl acetate (3x500ml), and the combined, dried organic extracts were evaporated to give the title compound as a gum (0.190g).
 10 T.l.c. System A (95:5:0.5) Rf 0.2.

Intermediate 6 was also made by the alternative two-step reaction as follows:-

(a) 1-Methyl-4-(2-methoxy-5-nitrophenyl)piperazine

1-(2-Methoxyphenyl)-4-methylpiperazine (5.36g) was acidified with 5N sulphuric acid and the excess water evaporated in vacuo. Concentrated sulphuric acid (95-98%, 22ml) was added and the mixture stirred at room temperature until homogeneous. To the stirred, dark solution was added portionwise at room temperature potassium nitrate (3.07g) in ten portions at intervals of approximately 5min. The mixture was stirred at room temperature for 4h then poured onto ice (-500ml) and the mixture made slightly alkaline with anhydrous sodium carbonate. The basic mixture was extracted with ethyl acetate (4x150ml) and the combined extracts dried. After 1h the mixture was filtered and the filtrate evaporated to dryness in vacuo. The dark red residue was diluted with ether (200ml) and the solid which separated (0.51g) was filtered off and discarded. The filtrate was evaporated to dryness and the oily residue mixed with ether (300ml) and the suspension filtered. The filtrate was evaporated to dryness to give a red gum which very slowly solidified to give the title compound (5.45g)
 20

25 T.l.c System A (150:8:1), Rf 0.45

(b) 4-Methoxy-3-(4-methyl-1-piperazinyl)benzenamine

To a solution of the product of step (a) (5.07g) in ethanol (70ml) was added a paste of Raney Nickel in water (2g). To the warmed suspension was added, with constant agitation, hydrazine hydrate (5ml) dropwise during 20min with occasional warming. After the main effervescence had ceased, the suspension was heated for 15min and then filtered with the aid of ethanol under nitrogen. The residues were kept moist and washed with ethanol and the combined filtrate and washings were evaporated to dryness with the aid of ethanol. The dark residue was re-evaporated with ethanol (20ml), resuspended in ether (40ml) and the mixture filtered. The residue was washed with ether and dried to give a solid consisting of the title compound (2.365g)
 30

35 T.l.c System A (70:8:1), Rf 0.25.

A further yield of the title compound (0.58g) was recovered from the ether filtrates and had t.l.c. (as above) Rf 0.25.

Intermediate 74-Bromo-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide

A solution of Intermediate 6 (0.168g) in pyridine (3ml) was treated with 4-bromobenzoyl chloride (0.25g) and stirred at 110°, under nitrogen, for 5h. Sodium bicarbonate (20ml; 8%) was added and the mixture was evaporated. The residue was pre-adsorbed onto silica gel [Merck Art. 7734 ca. 5g] and purified by SPC eluting with System A (97:3:0.3) to give the title compound as a beige solid (0.237g), m.p. 158.5-159.5°C.
 45

Intermediate 8

50 4-Iodo-2-methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide

65 A mixture of 4-iodo-2-methoxybenzoic acid (750mg) and thionyl chloride (7ml) was stirred at reflux for 15min and then evaporated to give 4-iodo-2-methoxybenzoyl chloride. A solution of Intermediate 6 (628mg) in THF (30ml) was treated with a solution of sodium hydroxide (227mg) in water (10ml), followed by the 4-iodo-2-methoxybenzoyl chloride, and the mixture stirred at 23° under nitrogen for 24h. 5M-Hydrochloric

acid (1.5ml) was added, followed by aqueous saturated sodium bicarbonate (10ml), and the mixture evaporated. The residue was treated with water (50ml), extracted with ethyl acetate (10x100ml), and the combined, dried organic extracts were evaporated. The residue was adsorbed from hot ethanol (Ca. 40ml) onto silica gel (Merck 7734, 10ml), and purified by FCC eluting with System A (945:50:5) to give a solid (780mg). Crystallisation from ethanol (10ml) gave the impure title compound, a portion of which (102mg) was recrystallised from ethanol to give the pure title compound as fine white crystals (37mg), m.p. 168-170°.

Intermediate 9

4-Bromo-N-[4-hydroxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide

A mixture of Intermediate 7 (0.5g) and pyridine hydrochloride (173mg) was heated at 180-200° for 2h. A further quantity of pyridine hydrochloride (600mg) was added and the mixture was heated at 180-200° for 16h. The resulting residue was mixed with aqueous sodium carbonate (2N;20ml) and extracted with dichloromethane (3x20ml). The dried extract was evaporated and the residue was purified on a column of silica eluting with System B (240:10:1) to give the title compound as a white foam (150mg). T.l.c System B (240:10:1), Rf 0.3

Intermediate 10

4-Methyl-3-pyridinylboronic acid

A solution of 3-bromo-4-methylpyridine (5.96g) in ether (20ml) was added dropwise to n-butyl lithium in hexane (1.57M;22ml) in ether (100ml) at -78° under nitrogen. After 10min stirring at -78° triisopropylborate (10.2ml) was added during 2min. The mixture was stirred at -78° for 30min and allowed to warm to room temperature during 2h. Water (30ml) was added and the organic layer was extracted with aqueous sodium hydroxide (0.5N; 33ml). The combined aqueous layers were washed with ether (30ml) and then acidified to pH6 with hydrochloric acid (2N). The mixture was stirred until the resulting gum had solidified. Filtration gave the title compound as a white solid (1.5g). n.m.r. (CD₃OD) δ 2.72 (3H,s), 7.88 (1H,brd), 8.58 (1H,brd), 8.69 (1H,brs).

Intermediate 11

4-Bromo-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methylbenzamide

4-Bromo-3-methylbenzoic acid (4.86g) in an excess of thionyl chloride (25ml) was heated to reflux for 1h. The excess thionyl chloride was then evaporated and the acid chloride then added to a mixture of a solution of Intermediate 6 (5.0g) in THF (25ml) and sodium hydroxide (1.8g) in water (30ml). The resulting solution was then stirred at room temperature, under nitrogen, overnight. The solvent was removed by evaporation, water (40ml) added and the mixture extracted with dichloromethane (5x50ml). The extracts were dried and evaporated to give a brown/orange sticky foam. This was purified by FCC eluting with System B (970:20:10) to give the title compound (5.73g). T.l.c. System B (970:20:10) Rf = 0.11

Intermediate 12

3,4-Dimethoxy-5-nitrobenzoic acid

To a solution of potassium permanganate (3.05g) in water (100ml) was added to a solution of 3,4-dimethoxy-5-nitrobenzaldehyde (2.7g) in acetone (80ml). The mixture was then stirred at 20° for 18h whereupon the acetone was evaporated and the residue acidified (2N HCl) and was then decolourised by the addition of sodium metabisulphite sodium. The mixture was then extracted with ethyl acetate (3x200ml) and the dried extracts evaporated to give the title compound as a colourless solid (2.08g) m.p. 197-198°.

Intermediate 13Methyl 3,4-dimethoxy-5-nitrobenzoate

- 5 Intermediate 12 (1g) was dissolved in methanol:conc. sulphuric acid (9:1; 20ml) and was stirred at 20° for 2h, and was then heated to reflux for 2h. The cooled mixture was added to 8% NaHCO₃ solution (50ml). The methanol was then evaporated and the residue extracted with ethyl acetate (2x75ml). The dried extracts were evaporated to give the title compound as a cream solid (1g), m.p. 75-76°.

10 Intermediate 14Methyl 3-amino-4,5-dimethoxybenzoate

- 15 A solution of Intermediate 13 (990mg) in ethanol (15ml) was hydrogenated over 10% palladium on carbon for about 5h. The mixture was filtered and was evaporated to give a pale pink oil which crystallised to give the title compound (883mg). T.l.c ethyl acetate:hexane (1:2) Rf 0.15.

Intermediate 1520 Methyl 3,4-dimethoxy-5-(4-methyl-1-piperazinyl)benzoate

- A mixture of Intermediate 14 (1.9g), 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (1.73g) and sodium carbonate (3.81g) in 3-methyl-3-pentanol (70ml) was heated to reflux for 42h. The solvent was evaporated and the residue partitioned between water (100ml) and ethyl acetate (2x100ml). The dried ethyl acetate extracts were evaporated to give a pale yellow oil (2.2g). This material was chromatographed eluting with System A (200:8:1) to give the title compound as a pale yellow oil which crystallised on standing (369mg).
T.l.c. System A (200:8:1) Rf 0.3

30 Intermediate 163,4-Dimethoxy-5-(4-methyl-1-piperazinyl)benzoic acid hydrazide

- 35 Intermediate 15 (651mg) was dissolved in methanol (15ml) containing hydrazine hydrate (2ml) and was heated to reflux for 18h. The cooled mixture was evaporated and the residue partitioned between water (30ml) and dichloromethane (2x30ml). The dried dichloromethane extracts were evaporated to give the title compound as a colourless solid (520mg). T.l.c. System A (100:8:1) Rf 0.20

Intermediate 1740 3,4-Dimethoxy-5-(4-methyl-1-piperazinyl)benzenamine

- 45 Intermediate 16 (510mg) in water (5ml) was treated with conc. HCl (5ml), cooled (0°), and a solution of sodium nitrite (144mg) in water (2ml) added over 5min. Stirring was continued at 0° for 20min, then at 20° for 1h. Conc. HCl (5ml) and glacial acetic acid (5ml) were then added, and the mixture heated to reflux for 2h. The cooled mixture was poured into 2N NaOH (100ml) and was then extracted with ethyl acetate (2x100ml). The dried extracts were evaporated to give a brown oil. This was chromatographed eluting with System A (100:8:1) to give the title compound as a red-brown oil which crystallised (139mg).
T.l.c. System A (100:8:1) Rf 0.20

50

Intermediate 184-Bromo-N-[3,4-dimethoxy-5-(4-methyl-1-piperazinyl)phenyl]benzamide

- 55 A mixture of Intermediate 17 (134mg) and 4-bromobenzoyl chloride (117mg) in THF (8ml) and water (4ml) was stirred at 20° for 3h in the presence of sodium hydroxide (42mg). The THF was evaporated and the residue was partitioned between water (25ml) and dichloromethane (2x50ml). The dried extracts were evaporated to give an off-white foam (240mg) which was chromatographed eluting with System A (200:8:1)

to give the title compound as an off-white foam (210mg).
T.l.c. System A (100:8:1) Rf 0.43.

Intermediate 19

1-(2-Methoxy-5-nitrophenyl)piperazine

Potassium nitrate (6.06g) was added portionwise during 2h to a solution of 1-(2-methoxyphenyl)piperazine (10.0g) in sulphuric acid (50ml; 95%) at room temperature. The resulting brown solution was stirred at room temperature for 30min and added cautiously to ice (300ml). The solution was basified with aqueous sodium hydroxide (5N) and extracted with ethyl acetate (2x400ml). The dried extract was evaporated and the residue was purified on a column of silica (190:10:1) to give the title compound as a yellow solid (9.4g). m.p. 102-104°C.

Intermediate 20

4-Methoxy-3-(1-piperazinyl)benzeneamine

A solution of Intermediate 19 (9.3g) in ethanol (100ml) was hydrogenated over 10% palladium on charcoal (1g) for 3h. The suspension was filtered and evaporated and the residue was purified on a column of silica eluting with System B (90:10:1) to give the title compound as a brown foam (7.5g).
T.l.c. System B (90:10:1), Rf 0.15.

Intermediate 21

1,1-Dimethylethyl 4-(5-amino-2-methoxyphenyl)-1-piperazinecarboxylate

A solution of di-tert butyl dicarbonate (3.3g) in dichloromethane (10ml) was added dropwise to a suspension of Intermediate 20 (3.0g) in TEA (4ml) and dichloromethane (20ml). The resulting solution was stirred for 2h and treated with aqueous sodium carbonate (2N; 50ml). The mixture was extracted with dichloromethane (3x50ml) and the dried extract was evaporated to give a yellow foam which was purified on a column of silica eluting with System B (240:10:1) to give the title compound as a yellow foam (1.9g).
T.l.c. System B (90:10:1), Rf 0.7.

Intermediate 22

1,1-Dimethylethyl 4-[5-[(4-bromobenzoyl)amino]-2-methoxyphenyl]-1-piperazinecarboxylate

A solution of 4-bromobenzoyl chloride (770mg) in THF (2ml) was added in one portion to a mixture of Intermediate 21 (1.0g), sodium hydroxide (200mg), water (10ml), and THF (10ml). The mixture was stirred for 30min, diluted with water (50ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified on a column of silica eluting with ether to give the title compound as a white solid (1.6g), m.p. 156-158°.

Intermediate 23

1,1-Dimethylethyl 4-[[2-methoxy-5-[4-(4-pyridinyl) benzoyl]amino]phenyl]-1-piperazinecarboxylate

A mixture of Intermediate 22 (1.0g), 4-pyridineboronic acid (250mg) tetrakis(triphenylphosphine)palladium (0) (50mg), DME (20ml), and aqueous sodium carbonate (2N; 4mmol) was refluxed under nitrogen for 2h. The mixture was treated with water (50ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified on a column of silica eluting with ethyl acetate to give the title compound as a white solid (750mg) mp 229-230°.

Intermediate 242-Fluoro-4-iodobenzoic acid

- 6 2-Fluoro-4-iodo-1-methylbenzene (1.0g) was added to a solution of potassium permanganate (2.0g) in water (25ml). The mixture was gently refluxed for 2h. Tetrabutylammonium bisulphate (100mg) was added and the mixture was refluxed for 18h. The cooled solution was treated with ethyl acetate (100ml) and water (50ml) and the brown suspension was filtered. The dried organic phase was evaporated and the resulting solid was partitioned between aqueous sodium bicarbonate (2N; 50ml) and diethyl ether (2x30ml). The basic solution
 10 was acidified with hydrochloric acid (2N) and extracted with dichloromethane (3x50ml). The dried extract was evaporated to give the title compound as a white solid (120mg), m.p. 158-159°.

Intermediate 25

- 16 4-Bromo-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2-methylbenzamide

A suspension of 4-bromo-2-methylbenzoic acid (706mg) in thionyl chloride (3ml) was refluxed under nitrogen for 3h and evaporated. The residual acid chloride was dissolved in THF (5ml) and added in one portion to a solution of Intermediate 6 (500mg) and sodium hydroxide (240mg) in THF (10ml) and water
 20 (5ml). The solution was stirred for 20min, diluted with water (50ml), and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified on a column of silica (Merck 9385) eluted with System B (485:15:1.5) to give the title compound as a yellow foam (630mg).
 T.l.c. System B (240:10:1), Rf 0.3.
 Similarly prepared was:-

25

Intermediate 26

2-Fluoro-4-iodo-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide as a yellow foam (870mg)

- 30 T.l.c. System B (240:10:1) Rf = 0.3

From a suspension of Intermediate 24 (800mg) in thionyl chloride (4ml), added in one portion to a solution of Intermediate 6 (663mg) in THF (20ml) and aqueous sodium hydroxide (2N; 6ml).

Intermediate 27

35

1-(2-Methyl-5-nitrophenyl)-4-methyl-2,6-piperazinedione

- A suspension of N-methyliminodiacetic acid (2.00g) in acetic anhydride (10ml) was stirred at room temperature for 10min and then heated to 150°C for 1h, after which time the solution had turned dark
 40 brown. The solution was concentrated in vacuo and about 10ml of distillate was collected. The resulting brown gum was then treated with 2-methyl-5-nitrobenzenamine (2.06g) suspended in toluene (20ml). The resulting mixture was heated to 100°C for 60min before allowing to cool overnight, giving a precipitate which was collected by filtration, washed with cold toluene (3x10ml) and then air-dried for 2 min. The solid was
 45 then added to a flask containing acetic anhydride (15ml) and heated to 140°C for 20 min. The mixture was then allowed to cool to 60°C before being concentrated in vacuo to give 10ml of distillate. The crystalline solid which was formed as the residue cooled was filtered off, washed with ether then recrystallised from methanol (20ml) to give the title compound as crystalline brown solid (1.78g), m.p. 157-158°C.

Intermediate 28

50

4-Methyl-1-(3-nitrophenyl)piperazine

- A solution of 1-(3-nitrophenyl)piperazine hydrochloride (1.80g) in water (7ml) was basified with anhydrous sodium carbonate (0.8g) and the mixture evaporated to dryness in vacuo. The solid was mixed with formic
 55 acid (17ml) and a solution of formaldehyde 36% in water (1.3ml, = 0.47g CH₂O) added and the mixture heated at 95-98° for 3h. The mixture was diluted with water (35ml) and basified with anhydrous sodium carbonate. The suspension was extracted with ethyl acetate (2x80ml) and the extract dried for 1h. The mixture was filtered and the filtrate evaporated to dryness to give a dark red oil which was dissolved in

ether (20ml) and filtered. The filtrate was evaporated to dryness to give a red oil which was purified by FCC eluting with System A (500:8:1) to give an orange oil which was dried in vacuo. Upon scratching, crystallisation began and the oil was left to stand until crystallisation of the title compound was complete (1.10g) m.p. 53-54°C.

6

Intermediate 291-(5-Amino-2-methylphenyl)-4-methyl-2,6-piperazinedione

- 10 A suspension of Intermediate 27 (1.70g) in ethanol:water (5:2, 50ml) was added under vacuum to a suspension of 10% palladium on charcoal 50% paste (600mg) in ethanol:water (5:2, 20ml). The resulting suspension was stirred at room temperature under an atmosphere of hydrogen until uptake ceased. The suspension was filtered, concentrated in vacuo, and the residue was dissolved in dichloromethane, dried, filtered and concentrated in vacuo to give the title compound as a cream coloured foam (1.51g) which was
- 15 dried in vacuo. T.l.c. System A (150:8:1), Rf = 0.41.
Similarly prepared was:-

Intermediate 30

- 20 3-(4-Methyl-1-piperazinyl)benzeneamine as a pale orange oil which crystallised after scratching and was dried in vacuo (0.904g), m.p. 75-76°C.

From a suspension of Intermediate 28 (1.10g) in ethanol:water (5:2, 20ml).

25 Intermediate 314-Methyl-3-(4-methyl-1-piperazinyl)benzenamine

- A solution of Intermediate 29 (1.48g) in dry THF (60ml) at reflux under nitrogen, was treated dropwise with borane-THF complex (1 molar solution, 25.5ml). The resulting mixture was heated at reflux under nitrogen for 22h before cooling and treating with 2N hydrochloric acid (10ml) very slowly. The mixture was then heated to reflux for a further 2h before cooling to room temperature and concentrating in vacuo to a volume of about 10ml. The residue was diluted with 2N sodium carbonate (100ml) and extracted with ethyl acetate (3x100ml). The combined, dried extracts were concentrated in vacuo and purified by FCC eluting with
- 35 System A (150:8:1) to give the title compound as a crystalline pale yellow solid (922mg) m.p. 83-84°C.

Intermediate 324-Bromo-N-[4-methyl-3-(4-methyl-1-piperazinyl)phenyl]benzamide

- 40 A solution of 4-bromobenzoyl chloride (1.469g) in THF (5ml) was added to a stirred solution of Intermediate 31 (915mg) in THF (15ml) and water (10ml) containing sodium hydroxide (350mg). The mixture was stirred at room temperature under nitrogen for 2½h before adding water (50ml) and extracting with dichloromethane (3x50ml). The combined extracts were dried and concentrated in vacuo to give a pale yellow foam. The
- 45 foam was dissolved in dichloromethane (5ml) to give a yellow solution which solidified. Excess dichloromethane was removed in vacuo and ether was added (25ml). The solid was triturated and then filtered, and dried in vacuo at 60°C for 2h to give the title compound as an off-white solid (1.46g) m.p. 208-209°C.
Similarly prepared was:-

50 Intermediate 334-Bromo-N-[3-(4-methyl-1-piperazinyl)phenyl]benzamide as a white solid (1.53g) m.p. 167-168°C.

- From a solution of 4-bromobenzoyl chloride (1.174g) in THF (4ml) and a stirred solution of Intermediate 30 (0.90g) in THF (15ml) and water (10ml) containing sodium hydroxide (380mg). Purification by FCC eluting with System A (350:8:1) gave the title compound.
- 55

Intermediate 342-Methoxy-3-(4-methyl-1-piperazinyl)benzoic acid

1-(2-Methoxyphenyl)-4-methylpiperazine (10.0g) was added in ether (20ml) dropwise to a solution of n-butyllithium in hexane (1.6M; 36ml) and N,N-tetramethylethylenediamine (5.6g) under nitrogen at room temperature. The resulting suspension was stirred for 6h and was added slowly to a mixture of solid carbon dioxide (50g) and THF (50ml). The mixture was allowed to warm to room temperature and was treated with water (150ml). The aqueous solution was washed with ether (2x200ml), acidified with hydrochloric acid (2N) and evaporated. The solid was treated with methanol (150ml), filtered and the filtrate was evaporated to give the title compound as a white solid (15.0g).

n.m.r. (D₂O) δ 3.04 and 3.0-3.15 (7H, m + s), 3.38 (2H, br.m), 3.65 (2H, br.d), 3.9 (3H, s), 7.15-7.35 (3H, m).

Intermediate 3515 Phenylmethyl [2-methoxy-3-[4-methyl-1-piperazinyl]phenyl]carbamate

Intermediate 34 (5g) was suspended in thionyl chloride (50ml) and refluxed for 3h under nitrogen. The excess thionyl chloride was removed by evaporation and the resulting solid was suspended in acetone (150ml). A solution of sodium azide (2.34g) in water (25ml) was added dropwise and the mixture was stirred for 2h. The solution was neutralised and was extracted with dichloromethane (3x100ml). The extract was washed with hydrochloric acid (2N; 100ml) and the acid phase was basified with aqueous sodium carbonate (2N) and extracted with dichloromethane (3x50ml). This extract was dried, evaporated and the residue was purified on a column of silica (Merck 9385) eluted with System B (485:15:1.5) to give the title compound as a brown gum (90mg).

25 T.l.c. System B (90:10:1), Rf 0.6.

Intermediate 362-Methoxy-3-(4-methyl-1-piperazinyl)benzenamine

30 A solution of Intermediate 35 (50mg) in benzyl alcohol (10ml) was treated with aqueous sodium hydroxide (5N; 2ml) and heated at gentle reflux for 4h. The solution was diluted with water (50ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated to give a benzyl alcohol phase. The benzyl alcohol solution was applied to a column silica (Merck 9385) eluted with ethyl acetate followed by ethyl acetate:methanol:ammonia (80:10:1) to give the title compound as a yellow gum (80mg).

35 T.l.c. System B (90:10:1) Rf 0.7

Intermediate 3740 4-Bromo-N-[2-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide

A solution of 4-bromobenzoyl chloride (150mg) in THF (1ml) was added in one portion to a solution of Intermediate 36 (120mg) and sodium hydroxide (40mg) in THF (3ml) and water (2ml). The mixture was stirred for 30 min and was treated with a further sample (150mg) of 4-bromobenzoyl chloride. The mixture was stirred for 1h, diluted with water (20ml) and extracted with dichloromethane (3x50ml). The dried extract was evaporated to give an orange solid which was triturated with ether (1ml) to give a yellow solid. The solid was purified on a column of silica (Merck 9385) eluted with System B (240:10:1) to give the title compound as a white solid (50mg).

T.l.c System B (90:10:1) Rf = 0.8.

Intermediate 383-Methoxy-4-[(trifluoromethylsulphonyl)oxy]benzoic acid

65 Trifluoromethanesulphonic anyhdride (10.0g, 6ml) in dry dichloromethane (50ml) was added dropwise to a stirred solution of 4-hydroxy-3-methoxybenzoic acid (4.0g) in dry dichloromethane (50ml) and pyridine (dry, 3.3ml) at 0°C under nitrogen. The reaction mixture was stirred at 0°C for a further 2h, sodium bicarbonate (8% solution) was added until basic and then the reaction mixture was extracted with ether (4x50ml).

Acidification of the evaporated ether residues with hydrochloric acid (2N) and extraction with dichloromethane (4 x 50ml) followed by evaporation to dryness gave a yellow/white solid (3.55g). This was purified by FCC eluting with hexane:ethyl acetate:acetic acid (740:250:10) to give the title compound as an off-white solid (1.43g) m.p. 120-122°C.

5

Intermediate 393-Methoxy-4-(4-pyridinyl)benzoic acid

- 10 Intermediate 38 (1.06g), 4-pyridinylboronic acid (486mg), DME (25ml), 2N sodium carbonate (10ml) and tetrakis(triphenylphosphine) palladium (0) (70mg), were heated to reflux for 18h under nitrogen. After allowing to cool to room temperature, water (50ml) was added and the mixture was washed with ethyl acetate (2x50ml). The aqueous phase was neutralised with 2N hydrochloric acid, and then concentrated in vacuo onto silica (Merck 9385). Purification by FCC eluting with ethyl acetate:hexane:acetic acid
- 15 (750:240:10) gave a pale orange solid which was triturated in ether and dried under high vacuum to give the title compound as a pale orange solid (370mg) m.p. 239-241 °C

Intermediate 401-(2-Chloro-5-nitrophenyl)-4-methylpiperazine

- A mixture of 2-chloro-5-nitrobenzenamine (7.95g) and 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (8.86g) in chlorobenzene (40ml) under nitrogen was heated to reflux for 3 days before cooling and diluting with dichloromethane (60ml). The reaction mixture was then extracted with water (2x500ml), the
- 25 aqueous layers combined and basified with 2N sodium hydroxide, then extracted with dichloromethane (4x400ml). The combined, dried extracts were concentrated in vacuo to give a dark brown oil (7.82g) which was purified by FCC eluting with ether to give a dark brown oil which crystallised upon standing. This material was dissolved in ethanol (40ml) and boiled up with some charcoal (300mg). The hot ethanolic suspension was filtered through a pad of hyflo and concentrated in vacuo to give the title compound as a
- 30 yellow oil which crystallised on standing (5.25g) m.p. 63-64 °C

Intermediate 411-(2-Fluoro-5-nitrophenyl)-4-methylpiperazine

- 35 A mixture of 2-fluoro-5-nitrobenzenamine (4.06g) and 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (5.01g) in chlorobenzene (20ml) was heated at reflux under nitrogen for 2½ days before cooling to room temperature. The dark tar-like material was dissolved in methanol (150ml), the solution then concentrated in vacuo with silica and the product purified twice by FCC eluting with System A (400:8:1)
- 40 followed by System A (300:8:1) to give the title compound as a crystalline brown solid (360mg).
T.l.c. System A (400:8:1) Rf = 0.15

Intermediate 424-Chloro-3-(4-methyl-1-piperazinyl)benzenamine

- 45 A solution of Intermediate 40 (5.06g) in ethanol (60ml) and water (10ml) was treated with Raney Nickel (2g of a slurry in water) under nitrogen. This mixture was cooled to 18 °C and treated dropwise with hydrazine hydrate (4ml) over 15 minutes. The resultant mixture was stirred at room temperature for 2 hours, filtered
- 50 and concentrated in vacuo to give an oil which crystallised upon cooling. The pale brown crystalline solid was dried in vacuo to give the title compound as a brown crystalline solid (4.36g). m.p. 96-97 °C.

Intermediate 434-Fluoro-3-(4-methyl-1-piperazinyl)benzenamine

- 55 A solution of Intermediate 41 (350mg) in ethanol and water (5:2, 10ml) was added under vacuum to a prehydrogenated suspension of 10% palladium on carbon, 50% paste (166mg) in ethanol and water (5:2,

4ml). The resulting suspension was stirred at room temperature under an atmosphere of hydrogen for 30 minutes. The suspension was filtered and the filter-cake washed with ethanol and water (5:2.50ml). The combined filtrates were concentrated in vacuo, the residue dissolved in dichloromethane (20ml) and dried. The filtered solution was concentrated in vacuo to give the title compound as a buff coloured solid (272mg).

5 m.p. 155-156°C.

Intermediate 44

4-Bromo-N-[4-chloro-3-(4-methyl-1-piperazinyl)phenyl]benzamide

10 A solution of Intermediate 42 (500mg) in dry THF (8ml) and water (8ml) containing sodium hydroxide (182mg), was treated with a solution of 4-bromobenzoyl chloride (730mg) in dry THF (4ml). The resulting mixture was stirred at room temperature for 4 hours. The mixture was added to water (50ml) and extracted with dichloromethane (3x40ml). The combined, dried extracts were concentrated in vacuo to give a yellow
15 foam which was triturated in dry ether (3x3ml) and dried in vacuo to give a cream-coloured solid (776mg). This was dissolved in methanol, concentrated in vacuo onto silica and purified by FCC eluting with System A (300:8:1) to give the title compound as a white solid (619mg) m.p. 204-205°
Similarly prepared was:-

Intermediate 45

4-Bromo-N-[4-fluoro-3-(4-methyl-1-piperazinyl)phenyl]benzamide as a cream-coloured solid (260mg) m.p. 125-127°C

25 From a solution of Intermediate 43 (245mg) in dry THF (4ml) and water (4ml) containing sodium hydroxide (94mg), treated with a solution of 4-bromobenzoyl chloride (390mg) in dry THF (2ml).

Intermediate 46

4-(2-Butoxyphenyl)-1-methylpiperazine

A stirred solution of 2-butoxybenzamine (6.50g) in chlorobenzene (50ml) was treated with 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (7.70g) according to the method of Intermediate 40. Concentration in vacuo of the dichloromethane extracts gave the title compound as a red oil (9.67g).
35 T.l.c: ether:hexane (5:1), Rf = 0.1.

Intermediate 47

4-(2-Butoxy-5-nitrophenyl)-1-methylpiperazine

40 Sulphuric acid (95%, 30ml) was added to Intermediate 46 (9.5g) and the resulting glassy/gummy mixture was stirred at room temperature until all material had dissolved. The solution was then treated portionwise with potassium nitrate (4.17g) over 45min at 25°C, and the mixture then stirred for 40min before pouring into ice (80ml) and basifying with 5N sodium hydroxide. The solution was extracted with ethyl acetate (4x500ml)
45 and the combined, dried extracts were concentrated in vacuo to give a dark orange oil (6.9g). Purification by FCC, eluting with ether, gave the title compound as a dark orange oil which crystallised on standing to give a yellow solid (4.597g), m.p. 72°C.

Intermediate 48

4-Butoxy-3-(4-methyl-1-piperazinyl)benzamine

A solution of Intermediate 47 (4.518g) in ethanol:water (5:2, 50ml) was added under vacuum to a pre-hydrogenated suspension of palladium (10% palladium on carbon, 50% paste with water, 0.9g) in ethanol:
65 water (5:2, 35ml). The resulting suspension was stirred at room temperature under an atmosphere of hydrogen. The catalyst was filtered off, the pad was washed with ethanol:water (70ml, 5:2) and the combined filtrates concentrated in vacuo to give a dark orange oil (4.5g). Purification by FCC eluting with System A (150:8:1) gave the title compound as a dark orange oil (3.88g).

T.l.c. System A (150:8:1), Rf 0.16.

Intermediate 49

6 4-Bromo-N-[4-butoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide

A stirred solution of Intermediate 48 (2.00g) in THF (30ml) was treated with a solution of sodium hydroxide (610mg) in water (30ml) and then 4-bromobenzoyl chloride (2.50g), according to the method of Intermediate 44. Purification by FCC eluting with System A (200:8:1) gave the title compound as a cream-coloured solid (1.71g). Concentration of earlier, impure fractions gave a solid which was triturated in ether and dried in vacuo to give a second batch of title compound as a cream-coloured solid (574mg) m.p. 142-144°C.

Intermediate 50

15 4-Methyl-3-pyridinylboronic acid, methyl ester

A solution of 3-bromo-4-methylpyridine (1g) in dry ether (3ml) was added over 8min (keeping the internal temperature below -72°) to a stirred, cooled (dry ice-acetone) solution of n-butyl lithium (1.69M; 3.6ml) in dry ether (18ml) under nitrogen. After a further 10min, triisopropylborate (1.85ml) was added over 3min. After a further 5min the cooling bath was removed and the mixture allowed to warm to room temperature over 1h. Water (30ml) and sodium hydroxide (2N; 3ml) were added and the aqueous layer washed with ether. The aqueous layer was adjusted to pH6 with 2N hydrochloric acid and then evaporated in vacuo to leave a semi-solid residue. The residue was re-evaporated with ethanol (20ml) and triturated with ether to give a white solid (1.4g). A sample (1.1g) of this solid was dissolved in warm (40°) methanol (17ml) and the solution filtered and seeded. Filtration gave the title compound (0.24g) as a white solid. T.l.c. methanol:triethylamine (95:5) Rf 0.21

Intermediate 51

30 2-Hydroxy-4-iodo-N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]benzamide

A suspension of 4-iodosalicylic acid (500mg) in thionyl chloride (5ml) was refluxed for 1h and evaporated. The residue in pyridine (3ml) was treated with Intermediate 6 (350mg) and the mixture was stirred at room temperature for 2h and at reflux for 16h. The mixture was diluted with dichloromethane (50ml) and washed with aqueous sodium bicarbonate (1N; 50ml). The dried organic phase was evaporated and the residue was purified by FCC eluting with System B (240:10:1) to give a yellow gum. The gum was triturated with ether (3ml) to give the title compound as a yellow powder (280mg). T.l.c. System B (90:10:1) Rf 0.45.

40 Intermediate 52

Methyl 4-bromo-3-methylbenzoate

4-Bromo-3-methylbenzoic acid (10g) was suspended in methanol (50ml) containing conc. sulphuric acid (2ml). The mixture was heated to reflux for 18h. On addition of 8% NaHCO₃ (100ml) to the cooled reaction, a flocculent solid was filtered off and dried in vacuo at 40-45° to give the title compound as a liquid which recrystallised on cooling (10.25g) m.p. 39.5-40.5°

Intermediate 53

50 Methyl 3-methyl-4-(4-pyridinyl)benzoate

A mixture of Intermediate 52 (736mg) and sodium carbonate (2N, 3ml) in DME (8ml) was treated with 4-pyridinylboronic acid (400mg) and tetrakis(triphenylphosphine)palladium (0) (25mg). The mixture was heated to reflux and stirred under nitrogen for 18 hours, before cooling to room temperature and adding to water (20ml). The mixture was extracted with dichloromethane (3x20ml) and the combined extracts dried and concentrated in vacuo to give a yellow oil. Purification by FCC eluting with System A (350:8:1) gave the title compound as a yellow oil which slowly recrystallised m.p. 70-71°C

Intermediate 54[4-[[[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]carbonyl] phenyl]boronic acid

- 5 n-Butyllithium (7.5ml of 1.6M solution in hexane) was added dropwise at -90 to -100° to a stirred solution of Intermediate 7 (404mg) and triisopropylborate (2.77ml) in dry THF (20ml) over 45min under nitrogen, and stirring continued for 1.5h at -90 to -103° for 1.5h. After 3h at -78°, the cooling bath was removed and the mixture stirred at +23° for 11h. Water (4ml) was added, and, after 1h, the mixture was evaporated. The residue was adsorbed from System A (50:45:5) onto silica gel (Merck 7734, 10ml) and purified by FCC
- 10 eluting with System A (89:10:1 → 50:45:5) to give firstly recovered impure starting material followed by the title compound as a cream foam (280mg)
- T.I.C. System A (50:45:5) Rf 0.04

Intermediate 55

- 15 4-Fluoro-2-methoxybenzenamine

- A solution of 5-fluoro-2-nitrophenol (10.0g) in dry acetone (40ml) under nitrogen was treated with potassium carbonate (8.9g). The mixture formed a deep red coloured thick precipitate. Methyl iodide (5ml, 11.4g) was
- 20 added slowly and the mixture stirred overnight and then at 60°C for 3 hours. Further methyl iodide (3ml, 6.84g) was added and the mixture stirred at 60°C for a further 3 hours. The mixture was added to water (50ml) and sodium hydroxide (2N, 40ml), and extracted with dichloromethane (3x100ml). The combined, dried extracts were concentrated in vacuo to give a yellow oil which upon cooling crystallised giving a pale yellow crystalline solid (10.88g). A solution of this solid in ethanol:water (200ml, 6:2) was added under
- 25 vacuum to a prehydrogenated suspension of palladium (10% on carbon, 50% paste, 2.5g) in ethanol:water (80ml, 6:2). The suspension was stirred under an atmosphere of hydrogen for 2 hours, the suspension was filtered through Hyflo. The combined filtrates were concentrated in vacuo and the moist residue re-evaporated with ethanol. The purple oily residue was dissolved in dichloromethane (200ml), dried and concentrated in vacuo to give the title compound as a dark purple liquid. (7.73g).

- 30 Analysis: Found: C, 59.8; H, 6.1; N, 9.8
C₇H₈FNO requires: C, 59.6; H, 5.7; N, 9.9%

Intermediate 56

- 35 1-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazine

- A mixture of Intermediate 55 (7.70g) and 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (11.7g) in chlorobenzene (60ml) was heated to reflux and stirred for 10 hours, then cooled to room temperature, diluted with dichloromethane (100ml) and extracted with water (3x100ml). The solution was
- 40 made slightly acidic with 2N hydrochloric acid, then basic (pH8-9) with 2N sodium hydroxide and extracted with dichloromethane (4x75ml). The combined, dried extracts were concentrated in vacuo to give a dark brown oily residue. This was purified by FCC eluting with System A (300:8:1) and dried in vacuo to give the title compound as a dark brown oil (1.312g).
- T.I.C. System A (150:8:1) Rf = 0.37

45

Intermediate 571-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-methylpiperazine

- 50 Intermediate 56 (1.25g) was added dropwise to conc. sulphuric acid (4ml). The mixture was stirred until complete solution of material was effected, and then treated portionwise at 25° with potassium nitrate (0.712g). The mixture was stirred at room temperature for 2 hours then poured into ice (20g). The aqueous solution was then neutralised with 0.88 aqueous ammonia and basified (pH8) with 2N sodium carbonate. The mixture was extracted with dichloromethane (4x10ml) and the combined, dried extracts concentrated in
- 55 vacuo to give the title compound as a dark orange oil (1.349g), which crystallised upon standing.

Intermediate 582-Fluoro-4-methoxy-5-(4-methyl-1-piperazinyl)benzenamine

- 6 A solution of Intermediate 57 (1.30g) in ethanol:water (7:2, 45ml) was added under vacuum to a prehydrogenated suspension of palladium on charcoal (10% Pd on C, 50% paste, 480mg) in ethanol:water (7:2, 18ml). The suspension was stirred under an atmosphere of hydrogen for 3 hours and filtered through hyflo. The combined filtrates and washings were evaporated to dryness and the residue dissolved in dichloromethane, dried, filtered and concentrated in vacuo to give the title compound as a purplish/brown solid (1.065g).
- 10 n.m.r. (CDCl₃) δ 2.35 (3H,s), 2.60 (4H,m), 3.01 (4H,m), 3.40 (2H,b.rs), 3.79 (3H,s), 6.43 (1H,d), 6.60 (1H,d).

Intermediate 5915 4-Bromo-N-[2-fluoro-4-methoxy-5-(4-methyl-1-piperazinyl)phenyl]-3-methylbenzamide

- A suspension of 4-bromo-3-methylbenzoic acid (606mg) in thionyl chloride (3ml) under nitrogen, was heated to reflux for 2 hours. The solution was evaporated to dryness in vacuo, the oily residue dissolved in THF (5ml) and the solution added slowly to a stirred solution of Intermediate 58 (657mg) in THF (30ml) and 2N sodium hydroxide (3ml). The mixture was stirred at room temperature for 4 hours, before pouring into water (100ml) and extracting with dichloromethane (3x100ml). The combined, dried extracts were concentrated in vacuo to give the title compound as a brown foam (940mg).
- 20 n.m.r. (CDCl₃) δ 2.36 (3H,s), 2.48 (3H,s), 2.62 (4H,m), 3.10 (4H,m), 3.85 (3H,s), 6.70 (1H,d), 7.52 (1H,dd), 7.65 (1H,d), 7.78 (2H,m), 7.99 (1H,d).

Intermediate 601-(2-Bromo-5-nitrophenyl)-4-methylpiperazine

- 30 A suspension of 2-bromo-5-nitrobenzenamine (26.0g) and 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (23.0g) in chlorobenzene (150ml) was treated according to the method of Intermediate 58. Purification by FCC eluting with System A (300:8:1 gradient to 200:8:1) gave the title compound as a brown solid (9.498g) m.p. 100-103°C.

35 Intermediate 614-Bromo-3-(4-methyl-1-piperazinyl)benzenamine

- A suspension of Intermediate 60 (8.68g) in ethanol (80ml) and water (20ml), under nitrogen, was treated with Raney nickel (-3g of a slurry with water). The suspension was then cooled to 17°C and maintained at a temperature below 28°C during the careful, slow addition of hydrazine hydrate (6ml), over 20 minutes. The cooled mixture was then stirred under nitrogen for 2 hours, then filtered through a pad of Hyflo. The combined filtrate and washings (ethanol:water; 6:1; 280ml) were concentrated in vacuo to give a gummy solid which was dissolved in dichloromethane, dried and evaporated in vacuo to give a dark grey/brown solid. The solid was triturated in hexane:ether (1:1, 50ml) overnight and the residue filtered and dried to give the title compound as a solid (3.28g). Further product was obtained by concentration of the filtrate in vacuo.
- 45 The resultant orange solid residue was purified by FCC eluting with System A (300:8:1) to give the title compound as a yellow solid (3.38g).m.p. 120 - 121.5°C.

50 Example 1N-[2-Methoxy-5-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl) benzamide

- 65 A stirred mixture of Intermediate 4 (400mg), 4-pyridinylboronic acid (122mg) tetrakis(triphenylphosphine)-palladium (0) (58mg), and anhydrous sodium carbonate (115mg) in water (18ml) and DME (18ml) was heated at reflux under nitrogen for 24h. Further 4-pyridinylboronic acid (61mg) was added and refluxing continued for a further 4h. The reaction mixture was poured into 2N sodium carbonate (30ml) and extracted with dichloromethane (3 x 75ml). The dried extracts were evaporated in vacuo to give a brown oil (500mg).

This was chromatographed on silica (Merck 7729, 30g) eluting with System A (200:8:1) to give the title compound as a yellow crystalline solid (147mg).

T.l.c. System A (100:8:1) Rf 0.42.

n.m.r. (CDCl₃) δ 2.37 (3H,s), 2.6 (4H,m), 3.2 (4H,m), 3.9 (3H,s), 6.66 (1H,dd), 6.87 (1H,d), 7.78 (2H, 1/2

5 AA'BB'), 8.02 (2H, 1/2 AA'BB'), 8.38 (1H,d), 8.62 (1H, br.s), 8.72 (2H, 1/2 AA'BB').

Similarly prepared :-

Example 2

10 N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)-benzamide as a yellow solid (90mg), m.p. 183-185°C.

Analysis Found :	C,71.3;	H,6.55;	N,13.6.
C ₂₄ H ₂₆ N ₄ O ₂ 0.07 CH ₃ CO ₂ C ₂ H ₅ requires	C,71.4;	H,6.55;	N,13.7%.

From Intermediate 7 (0.160g) and 4-pyridinylboronic acid (0.054g). Purification by SFC eluting with System A (98:4:0.4) afforded the title compound.

Example 3

4-(4-Pyridinyl)-2-methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]benzamide

25 A mixture of Intermediate 8 (532mg) and 4-pyridinylboronic acid (272mg) in DME (18ml) was treated with a solution of sodium carbonate (351mg) in water (9ml) followed by tetrakis (triphenylphosphine)palladium (0) (51mg) and the mixture stirred at reflux under nitrogen for 10h. The mixture was evaporated, treated with water (40ml) and extracted with ethyl acetate (6x50ml). The aqueous phase was filtered and the precipitate collected to give solid (I). The combined, dried organic extracts were evaporated and the residue combined with solid (I). The combined product was purified by FCC eluting with System A (945:50:5) to give the crude title compound (540mg). This crystallised from ethyl acetate (10ml) to give the pure title compound as pale cream crystals (204mg). T.l.c System A (89:10:1) Rf 0.26.

Analysis Found	C,69.1;	H,6.5;	N,12.6;
C ₂₅ H ₂₈ N ₄ O ₃ requires	C,69.4;	H,6.5;	N,12.95%

Similarly prepared:-

Example 4

N-[4-Hydroxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl) benzamide as a white solid (85mg) m.p. 157-160°C.

45 T.l.c. System B (90:10:1) Rf = 0.5.

From a mixture of Intermediate 9 (150mg), 4-pyridinylboronic acid (50mg), tetrakis(triphenylphosphine)-palladium (0) (20mg), DME (4ml) and sodium carbonate (2N; 1ml). Purification by crystallisation from isopropanol afforded the title compound.

Example 5

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-methyl-3-pyridinyl)benzamide as a cream-coloured foam (145mg) m.p. 77°-81°C.

65 T.l.c.System A (980:10:10), Rf=0.10.

From a mixture of Intermediate 7 (300mg), Intermediate 10 (100mg), sodium carbonate (2N; 2ml), DME (8ml) and tetrakis(triphenylphosphine)palladium (0) (50mg). Purification by FCC eluting with System A (980:10:10 → 940:50:5) afforded the title compound.

Example 6

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide as a cream-coloured solid (241mg) m.p. 208°-210°C.

Analysis Found:	C,71.3;	H,6.7;	N,12.9
C ₂₅ H ₂₈ N ₄ O ₂ ·0.34 H ₂ O requires	C,71.0;	H,6.8;	N,13.2%

Water Assay Found: 0.10%w/w H₂O = 0.34 mol % H₂O

From a mixture of Intermediate 11 (300mg) 4-pyridinylboronic acid (88mg) sodium carbonate (2N, 2ml), DME (8ml) and tetrakis (triphenylphosphine)palladium (0) (50mg). Purification by FCC eluting with System B (980:10:10) afforded the title compound.

Example 7

N-[3,4-Dimethoxy-5-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide

A mixture of Intermediate 18 (208mg), 4-pyridinylboronic acid (59mg), sodium carbonate (167mg) and tetrakis(triphenylphosphine)palladium (0) (27mg) in 1:1 aqueous DME (18ml) was heated to reflux for 6h. The mixture was allowed to cool, silica gel (Merck 9385, 5g) was added, and the solvents evaporated. The residue was chromatographed eluting with System A (200:8:1) to give the title compound as an off-white solid (112mg), m.p. 219-221°.

Assay Found:	C,68.9;	H,8.85;	N,12.5;
C ₂₅ H ₂₈ N ₄ O ₃ requires	C,69.4;	H,8.55;	N,12.95%

Example 8

N-[4-Methoxy-3-(1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide

A mixture of Intermediate 23 (550mg), hydrochloric acid (3N; 10ml), and ethyl acetate (50ml) was stirred at room temperature for 4h. The resulting solution was treated with aqueous sodium carbonate (2N; 25ml) and extracted with dichloromethane (5x50ml). The dried extract was evaporated and the residue was purified on a column of silica eluting with System B (90:10:1) to give the title compound as a yellow solid (200mg), m.p. 77-79°.

T.l.c. System B (90:10:1), Rf 0.2.

Example 9

N-[3-(4-Ethyl-1-piperazinyl)-4-methoxyphenyl]-4-(4-pyridinyl)benzamide

A mixture of the product of Example 8 (110mg), acetaldehyde (34mg), acetic acid (72mg) and methanol (5ml) was stirred for 10min under nitrogen at room temperature. The resulting brown solution was treated in one portion with sodium cyanoborohydride (25mg) and stirred for 3h. The mixture was basified with aqueous sodium carbonate (2N) and extracted with dichloromethane (3x50ml). The dried extract was evaporated and the residue was purified twice on a column of silica eluting with System B (240:10:1) to give the title compound as a yellow foam (40mg).

T.l.c. System B (90:10:1), Rf 0.5.

n.m.r (CDCl₃) δ 1.15 (3H,t), 2.53 (2H,q), 2.68 (4H,br.s), 3.18 (4H, br.s), 3.88 (3H,s), 6.88 (1H,d), 7.22 (1H,d), 7.32 (1H,dd), 7.55 (2H, 1/2AA'BB'), 7.76 (2H, 1/2 AA'BB'), 7.80 (1H,br.s), 8.0 (2H, 1/2AA'BB'), 8.72 (2H, 1/2AA'BB').

Example 10N-[2-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide

- 5 A mixture of Intermediate 37 (42mg), 4-pyridinylboronic acid (19mg) tetrakis(triphenylphosphine)palladium (0) (5mg), aqueous sodium carbonate (2N;1ml) and DME (4ml) was refluxed under nitrogen for 18h. The solution was added to water (25ml) and extracted with dichloromethane (2x25ml). The dried extract was evaporated and the residue was triturated with ether (2ml) to give the title compound as a white powder (20mg) m.p. 153-155°.

10 Tlc System B (90:10:1) Rf 0.7.

Similarly prepared were:-

Example 11

- 15 N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2-methyl-4-(4-pyridinyl)benzamide as a white solid (110mg) m.p. 183-184°C.

T.l.c. System B (240:10:1) Rf = 0.15

- 20 From a mixture of Intermediate 25 (200mg), 4-pyridinylboronic acid (74mg), tetrakis(triphenylphosphine)-palladium (0) (10mg), DME (8ml), and aqueous sodium carbonate (2N; 2ml). Purification by column chromatography eluting with System B (240:10:1) afforded the title compound.

Example 12

- 25 2-Fluoro-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide as a yellow solid (160mg) m.p. 203-204°C.

T.l.c System B (240:10:1) Rf = 0.2

- 30 From a mixture of Intermediate 26 (250mg), 4-pyridinylboronic acid (74mg), tetrakis(triphenylphosphine)-palladium (0) (10mg), aqueous sodium carbonate (2N; 2ml), and DME (8ml). Purification by column chromatography eluting with System B (240:10:1) afforded the title compound.

Example 13

- 35 N-[3-(4-Methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide

- 40 A solution of Intermediate 33 (277mg), in DME (8ml) and 2N sodium carbonate (2ml) containing tetrakis-(triphenylphosphine)palladium (0) (20mg) was treated with 4-pyridinylboronic acid (100mg). The resulting mixture was stirred under nitrogen for 10min, then heated to reflux for 5h before cooling to room temperature and standing overnight. The mixture was then added to water (50ml) and extracted with dichloromethane (3x50ml) then dichloromethane:ethanol (10:1) (50ml). The combined, dried extracts were concentrated in vacuo to give a fine white powder-like solid which was purified by FCC eluting with System A (200:8:1) to give the title compound as a yellow solid, which was dried in vacuo at 60°C for 22h (109mg) m.p. 232-233°C.

45 T.l.c. System A (150:8:1) Rf = 0.05

Similarly prepared was:-

Example 14

- 50 N-[4-Methyl-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide as a cream-coloured crystalline solid (160mg) m.p. 225-226°C

55

Analysis Found:	C,73.8;	H,6.8;	N,13.8;
C ₂₄ H ₂₆ N ₄ O.0.12C ₂ H ₆ O requires	C,74.3;	H,6.8;	N,14.2%

N.m.r. - 0.12mol ethanol present per mol compound

From a solution of Intermediate 32 (287mg) in DME (8ml) and 2N sodium carbonate (2ml) containing tetrakis(triphenylphosphine) palladium (0) (20mg), treated with 4-pyridinylboronic acid (100mg).

6 Example 15

3-Methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide

10 A suspension of Intermediate 39 (300mg) in thionyl chloride (5ml) was heated to reflux under nitrogen for 1h. After this time complete solution of material was seen and a yellow solid precipitated over the next 30min. Excess thionyl chloride was removed in vacuo to leave a pale yellow solid - the acid chloride - which was added to a solution of Intermediate 6 (290mg) in dry pyridine (5ml). The mixture was stirred at room temperature for 1h and then concentrated in vacuo to give a dark yellow solid residue which was dissolved in water (50ml) and extracted with dichloromethane (3x50ml). The combined, dried extracts were concentrated in vacuo and purified by FCC eluting with System A (250:8:1) to give a yellow solid which was dried in vacuo at 60°C to give a yellow solid. Recrystallisation from isopropanol (4ml) afforded the title compound as a pale yellow crystalline solid (220mg), m.p. 196-197°C, after drying in vacuo at 60-80°C for 15h.

20

Analysis Found:	C,68.8;	H,6.5;	N,12.8;
C ₂₅ H ₂₈ N ₄ O ₃ .0.45C ₃ H ₈ O requires	C,68.9;	H,6.9;	N,12.2%

N.m.r.- contains 0.45mol of isopropanol per mol compound

25

Example 16

N-[4-Chloro-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide

30 A mixture of Intermediate 44 (250mg) in DME (8ml) and 2N sodium carbonate (2ml) containing tetrakis-(triphenylphosphine)palladium (0) (20mg) was treated with 4-pyridinylboronic acid (100mg) under nitrogen and stirred for 10min before heating to reflux for 1.5h. The reaction mixture was then cooled to room temperature, added to water (25ml) and extracted with dichloromethane (3x25ml). The combined, dried extracts were concentrated in vacuo to give a yellow oil (343mg) which crystallised on standing overnight. 35 The solid was dissolved in ethanol and concentrated in vacuo onto silica (Merck 9385). Purification by FCC eluting with System A (125:8:1) gave a pale yellow foam which was triturated with ether to give the title compound as a cream-coloured solid (202mg), m.p. 218-219°C

40

Analysis Found:	C,67.8;	H,5.9;	N,13.3;
C ₂₃ H ₂₃ ClN ₄ O.0.15(CH ₃ CH ₂) ₂ O requires	C,67.7;	H,5.8;	N,13.6%

N.m.r. indicates 0.15mol ether per mol of compound.
Similarly prepared were:-

45

Example 17

N-[4-Fluoro-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide as an off-white solid (215mg) m.p. 205-206°C

50

Analysis Found:	C,70.9;	H,6.3;	N,13.85;
C ₂₃ H ₂₃ FN ₄ O.0.35C ₄ H ₁₀ O requires	C,70.4;	H,6.4;	N,13.45%

55

n.m.r. indicated 0.35 mol ether per mol compound

From a mixture of Intermediate 45 (250mg) in DME (8ml) and 2N sodium carbonate (2ml) containing tetrakis(triphenylphosphine)palladium (0) (20mg) treated with 4-pyridinylboronic acid (90mg).

Example 18

N-[4-Butoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide as a pale yellow powder (298mg)
m.p. 205-207°C

T.l.c. System A (75:8:1) Rf = 0.25.

From a stirred solution of Intermediate 49 (316mg) in DME (8ml) containing 2N sodium carbonate (2ml) and tetrakis(triphenylphosphine)palladium (0) (20mg), treated with 4-pyridinylboronic acid (100mg).

Example 19

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)-4-(3-methyl-4-pyridinyl)benzamide as a pale yellow foam (68mg)

Analysis Found:	C,69.4;	H,8.6;	N,12.6;
C ₂₅ H ₂₈ N ₄ O ₂ 0.8H ₂ O requires	C,69.7;	H,8.9;	N,13.0%

n.m.r. (CDCl₃) δ 2.28 + 2.38 (6H, 2xs), 2.63 (4H,br.m), 3.15 (4H,br.m), 3.88 (3H,s), 6.87 (1H,d), 7.16 (1H,d), 7.2-7.35 (2H,m), 7.44 (2H, 1/2 AA'BB'), 7.79 (1H,br.s), 7.97 (2H, 1/2 AA'BB'), 8.48-8.52 (2H, br.s).

From a solution of 4-bromo-3-methylpyridine hydrochloride (777mg) in water (3ml), treated with sodium hydrogen carbonate until effervescence stopped. The solution was then treated with 2N sodium carbonate (2ml), DME (10ml), tetrakis(triphenylphosphine)palladium (0) (100mg) and Intermediate 54 (430mg).

Example 20

N-[6-Fluoro-4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide as off-white crystals (173mg) m.p. 92-93°C

Analysis Found:	C,62.9;	H,6.2;	N,11.4;
C ₂₅ H ₂₇ FN ₄ O ₂ 2.4H ₂ O requires	C,62.8;	H,6.7;	N,11.7%

From a solution of Intermediate 59 (405mg) in DME (12ml) and 2N sodium carbonate (3ml), treated with 4-pyridinylboronic acid (115mg) and tetrakis(triphenylphosphine)palladium (0) (30mg).

Example 21

2-Hydroxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-methyl-3-pyridinyl)benzamide

A mixture of Intermediate 51 (250mg), Intermediate 50 (91mg), tetrakis(triphenylphosphine)palladium (0) (10mg), aqueous sodium carbonate (2N;2ml), and DME (10ml) was refluxed for 16h under nitrogen. The cooled mixture was added to water (30ml) and extracted with dichloromethane:methanol (19:1) (3x100ml). The dried extract was evaporated and the residue was purified by FCC eluting with System B (240:10:1) to give a yellow foam. The foam was triturated with ether (2ml) to give the title compound as a white foam (75mg).

T.l.c. System B (90:10:1) Rf 0.5.

n.m.r. (CDCl₃) δ 2.32 + 2.38 (6H, 2xs), 2.67 (4H,m), 3.15 (4H,br.m), 3.89 (3H,s), 5.2(1H,vbr.s), 6.88 (2H,d + dd), 6.99 (1H,d), 7.12 (1H,d), 7.22 (1H,br.d), 7.30 (1H,dd), 7.75 (1H,d), 8.45-8.55 (3H, vbr.s + br.s + br.d).

Example 22

N-[4-Bromo-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide

A solution of Intermediate 61 (150mg) in dimethyl sulfoxide (1ml), was treated under nitrogen at room temperature with sodium hydride (30mg, 60% dispersion in oil) and stirred for 10 minutes. The mixture was

EP 0 533 267 A1

then treated with a solution of Intermediate 53 (152mg) in dimethyl sulphoxide (0.5ml). The mixture was stirred at room temperature for 2 days before adding additional Intermediate 53 (30mg). The mixture was poured into water (3ml) and extracted with dichloromethane (2x4ml). The combined, dried extracts were concentrated in vacuo to give a yellow oil which was triturated in ether to give the title compound as a cream-coloured powdery solid (116mg) m.p. 240-241°C

Analysis Found:	C, 81.8;	H, 5.4;	N, 11.85
C ₂₄ H ₂₅ BrN ₄ O Requires:	C, 81.8;	H, 5.4;	N, 12.0%

The following examples illustrate pharmaceutical formulations according to the invention. The term "active ingredient" is used herein to represent a compound of formula (I).

Pharmaceutical Example 1

Oral Tablet A	
Active Ingredient	700mg
Sodium starch glycollate	10mg
Microcrystalline cellulose	50mg
Magnesium stearate	4mg

Sieve the active ingredient and microcrystalline cellulose through a 40 mesh screen and blend in a appropriate blender. Sieve the sodium starch glycollate and magnesium stearate through a 60 mesh screen, add to the powder blend and blend until homogeneous. Compress with appropriate punches in an automatic tablet press. The tablets may be coated with a thin polymer coat applied by the film coating techniques well known to those skilled in the art. Pigments may be incorporated in the film coat.

Pharmaceutical Example 2

Oral Tablet B	
Active Ingredient	500mg
Lactose	100mg
Maize Starch	50mg
Polyvinyl pyrrolidone	3mg
Sodium starch glycollate	10mg
Magnesium stearate	4mg
Tablet Weight	667mg

Sieve the active ingredient, lactose and maize starch through a 40 mesh screen and blend the powders in a suitable blender. Make an aqueous solution of the polyvinyl pyrrolidone (5 - 10% w/v). Add this solution to the blended powders and mix until granulated; pass the granulate through a 12 mesh screen and dry the granules in a suitable oven or fluid bed dryer. Sieve the remaining components through a 60 mesh screen and blend them with the dried granules. Compress, using appropriate punches, on an automatic tablet press.

The tablets may be coated with a thin polymer coat applied by film coating techniques well known to those skilled in art. Pigments may be incorporated in the film coat.

Pharmaceutical Example 3

Inhalation Cartridge	
Active Ingredient	1mg
Lactose	24mg

Blend active ingredient, particle size reduced to a very fine particle size (weight mean diameter ca. 5µm) with the lactose in a suitable powder blender and fill the powder blender into No. 3 hard gelatin capsules.

The contents of the cartridges may be administered using a powder inhaler.

Pharmaceutical Example 4


Injection Formulation	
	% w/v
Active ingredient	1.00
Water for injections B.P. to	100.00

Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the active ingredient using dilute acid or alkali or by the addition of suitable buffer salts. Antioxidants and metal chelating salts may also be included.

The solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions. The solution may be packed under an inert atmosphere of nitrogen.

Claims


1. A compound of the general formula (I) :



or a physiologically acceptable salt or solvate thereof wherein

R¹ represents a hydrogen atom, a halogen atom or a group selected from C₁₋₆ alkyl and C₁₋₆ alkoxy;
 R² represents a pyridinyl group optionally substituted by one or two substituents selected from halogen atoms, C₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkoxyC₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, -CN, -NO₂, -CO₂R⁶, -COR⁶, -CONR⁶R⁷ and -(CH₂)_mOC(O)C₁₋₆ alkyl;

R³ represents the group




R⁴ and R⁵, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C₁₋₆ alkoxy and C₁₋₆ alkyl;

R⁶, R⁷ and R⁸, which may be the same or different, each independently represent a hydrogen atom or

a C₁₋₆ alkyl group; and
m represents zero or an integer from 1 to 3.

2. A compound as claimed in Claim 1 wherein R² represents a 3- or 4-pyridinyl group, especially a 4-pyridinyl group, optionally substituted by one or two substituents selected from halogen atoms or C₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkoxyC₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, -CN, -NO₂, -CO₂R⁶, -COR⁶, -CONR⁶R⁷ and -(CH₂)_mOC(O)C₁₋₄ alkyl.
3. A compound as claimed in Claim 1 or Claim 2 wherein R² represents a pyridinyl group optionally substituted by a single substituent selected from halogen atoms, C₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkoxyC₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, -CN, -NO₂, -CO₂R⁶, -COR⁶, -CONR⁶R⁷ and -(CH₂)_mOC(O)C₁₋₄ alkyl, preferably a C₁₋₆ alkyl group, most preferably a methyl group.
4. A compound as claimed in Claim 3 wherein the single substituent on the pyridinyl group is in a position ortho to the bond to the phenyl ring A in general formula (I).
5. A compound as claimed in any one of Claims 1 to 4 wherein R¹ is a hydrogen atom, a halogen atom, especially a fluorine atom, or a group selected from C₁₋₃ alkyl, especially methyl, and C₁₋₃ alkoxy, especially methoxy.
6. A compound as claimed in any one of Claims 1 to 5 wherein R⁴ is attached at the para-position relative to the amide linkage.
7. A compound as claimed in any one of Claims 1 to 6 wherein R⁴ represents a hydrogen atom or a halogen atom, especially a fluorine or chlorine atom, or a hydroxy, C₁₋₃ alkoxy, especially methoxy, or C₁₋₃ alkyl, especially methyl, group.
8. A compound as claimed in any one of Claims 1 to 7 wherein R⁵ is a hydrogen atom or a C₁₋₆ alkoxy group, especially a methoxy group.
9. A compound as claimed in any one of Claims 1 to 8 wherein R⁸ is a hydrogen atom or a C₁₋₃ alkyl group, especially a methyl group.
10. A compound of the general formula (I) as claimed in Claim 1 or a physiologically acceptable salt or solvate thereof wherein
R¹ represents a hydrogen atom, a halogen atom or a group selected from C₁₋₆ alkyl and C₁₋₆ alkoxy;
R² represents a pyridinyl group optionally substituted by a C₁₋₆ alkyl group;
R⁵ represents the group




- R⁴ and R⁵, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy and C₁₋₆ alkoxy; and
R⁶, R⁷ and R⁸, which may be the same or different, each independently represent a hydrogen atom or a C₁₋₆ alkyl group.
11. The compound:
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide, and physiologically acceptable salts and solvates thereof.
12. A compound selected from:
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl) benzamide;
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-methyl-3-pyridinyl)benzamide;
N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2-methyl-4-(4-pyridinyl)benzamide;
N-[4-methyl-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;


N-[4-chloro-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
 N-[4-fluoro-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
 N-[4-methoxy-3-(4-methyl-1-piperazinyl)-4-(3-methyl-4-pyridinyl)benzamide;
 N-[6-fluoro-4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;
 N-[4-bromo-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;
 N-[3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
 4-(4-pyridinyl)-2-methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzamide;
 N-[4-hydroxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)benzamide;
 and physiologically acceptable salts and solvates thereof.

13. A process for the preparation of a compound as claimed in any one of Claims 1 to 12 or a physiologically acceptable salt or solvate thereof which comprises:

(1) reacting an aniline (II)




wherein R³, R⁴ and R⁵ are as defined in general formula (I), with a halophenyl compound (III)




wherein Y represents a halogen atom or the group -OSO₂CF₃, and R¹ and R² are as defined in general formula (I), in the presence of carbon monoxide and a catalyst, followed, if necessary, by the removal of any protecting group where present; or

(2) treating compound of formula (IV)




with an amine dihalide of formula (V)




wherein Hal is a chlorine, bromine or iodine atom, followed, if necessary, by the removal of any protecting group where present; or


(3) reacting an aniline of formula (II) with an activated carboxylic acid derivative of formula (VI)




10 wherein L is a leaving group, followed, if necessary, by the removal of any protecting group where present; or
(4a) treating a compound of formula (VIIIa).




20 wherein Y represents a bromine or iodine atom or the group $-\text{OSO}_2\text{CF}_3$, with a compound of formula (IXa)



or an ester or an anhydride thereof, or
(4b) treating a compound of formula (VIIIb)



35 or an ester or an anhydride thereof, with a compound of formula (IXb)



wherein Y represents a bromine or iodine atom or the group $-\text{OSO}_2\text{CF}_3$, followed, if necessary, by the removal of any protecting group where present;
and when the compound of general formula (I) is obtained as a mixture of enantiomers, optionally resolving the mixture to obtain the desired enantiomer;
45 and/or, if desired, converting the resulting compounds of general formula (I) or a salt thereof into a physiologically acceptable salt or solvate thereof.

14. A pharmaceutical composition comprising at least one compound of general formula (I) as defined in any one of Claims 1 to 12 or a physiologically acceptable salt or solvate thereof, together with at least one physiologically acceptable carrier or excipient.

15. A compound of general formula (I) as claimed in any one of Claims 1 to 12 or a physiologically acceptable salt or solvate thereof for use in therapy, for example,

- 55 (i) for use in the treatment or prophylaxis of depression; or
(ii) for use in the treatment or prophylaxis of CNS disorders, selected from mood disorders such as seasonal affective disorder and dysthymia; anxiety disorders such as generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders such as dementia, amnesic disorders and age-associated memory

impairment; and disorders of eating behaviour such as anorexia nervosa and bulimia nervosa; or
(iii) for use in the treatment or prophylaxis of a disease selected from Parkinson's disease, dementia
in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; or
(iv) for use in the treatment or prophylaxis of endocrine disorders, vasospasm, hypertension,
disorders of the gastrointestinal tract where changes in motility and secretion are involved, and
sexual dysfunction.

5

10

16. A compound of general formula (I) as claimed in any one of Claims 1 to 12 or a physiologically
acceptable salt or solvate thereof and an antidepressant agent in the presence of each other in the
human or non-human animal body for use in the treatment of depression.

15

17. A compound of general formula (I) as claimed in any one of Claims 1 to 12 or a physiologically
acceptable salt or solvate thereof and an antiparkinsonian agent in the presence of each other in the
human or non-human animal body for use in the treatment of Parkinson's disease, dementia in
Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias.

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 92 20 2805

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
A	EP-A-0 058 779 (DR. KARL THOMAE GMBH) 1 September 1982 * claims *	1-17	C07D213/56 A61K31/50
A	DE-A-2 545 978 (CHUGAI SEIYAKU K.K.) 22 April 1976 * claims *	1-17	
A	ARCHIV DER PHARMAZIE vol. 315, no. 2, February 1982, WEINHEIM pages 97 - 103 E.S. CHARLES ET AL. 'SYNTHESIS OF SUBSTITUTED BENZAMIDES, BENZIMIDAZOLES AND BENZOXAZINES AS POTENTIAL ANTHELMINTIC AND ANTIMICROBIAL AGENTS' * the whole document *	1-17	
A	EP-A-0 210 782 (DAINIPPON PHARMACEUTICAL CO. LTD) 4 February 1987 * claims *	1-17	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
			C07D A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 04 DECEMBER 1992	Searcher SANCHEZ GARCIA J.M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	

EPO FORM 180 (01.92)